MedTrace Logo

Non-invasive Support in Extremely Preterm Infants

NCT02723123 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-22

No results posted yet for this study

Summary

Non-invasive respiratory support is routinely provided to extremely preterm infants following disconnection from mechanical ventilation, in the form of continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV). However, these modes remain sub-optimal due to lack of synchronization and upper airway defensive mechanisms that potentially hinder their effectiveness. Non-invasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) is a novel mode that may overcome some of these problems but has not been investigated in this population. Investigators hypothesize that there will be significant differences in cardiorespiratory behavior in extremely preterm infants receiving CPAP, NIPPV and NIV-NAVA during the immediate post-extubation period.

Conditions

  • Noninvasive Ventilation

Interventions

OTHER

Recording of cardio-respiratory signals

Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.

Sponsors & Collaborators

  • Guilherme Sant'Anna, MD

    lead OTHER

Principal Investigators

  • Guilherme Sant'Anna, MD · McGill University

  • Wissam Shalish, MD · McGill University

  • Robert Kearney, PhD · McGill University

  • Karen Brown, MD · McGill University

  • Doina Precup, PhD · McGill University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723123 on ClinicalTrials.gov